Drug intelligence / Profile preview

anti-CS6 BSIgG

Development stage
Phase 1
Lead developer
SAB Biotherapeutics
Modality
Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
Administration
Oral
01

Overview

Anti-CS6 BSIgG is a hyperimmune bovine serum immunoglobulin G preparation generated by immunizing cattle with the colonization factor antigen CS6 from enterotoxigenic *Escherichia coli* (ETEC). The resulting antibodies are purified from bovine serum and administered orally as a passive prophylactic agent to prevent ETEC-induced diarrhea. The mechanism of action involves binding to the CS6 colonization factor on ETEC, theoretically blocking bacterial adherence to intestinal epithelial cells and preventing infection. In clinical studies, anti-CS6 BSIgG was well tolerated but did not demonstrate significant efficacy in preventing moderate-severe diarrhea following challenge with CS6-expressing ETEC strain B7A[1][3][4][5]. The product is developed and manufactured by SAB Biotherapeutics.

Other names
hyperimmune bovine serum immunoglobulin G against CS6anti-CS6 bovine serum IgGanti-CS-6 bovine serum IgGanti-CS 6 bovine serum IgG
02

Targets

CS6 (Colonization factor antigen 6)

Beyond the preview

Go deeper on anti-CS6 BSIgG.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on anti-CS6 BSIgG.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call